Preliminary Final Report
Released
Released
Announcement PDF
ASX Announcement
Appendix 4E: Preliminary Financial Report
under ASX Listing Rule 4.3A
Current reporting period: Year ended 30 June 2026
Prior corresponding period: Year ended 30 June 2025
Results for announcement to the market
30 June 2026
$’000
30 June 2025
$’000 Movement %
Reported
Revenue 12,050 4,912 Up 145%
Loss for the period attributable to members (7,465) (9,990) Down 25%
Dividends
No dividends were paid or declared during the current period or during the previous corresponding period.
Explanation of Revenue
Revenue for the year was $12,050,000 (2025: $4,912,000) and included an $8,340,000 upfront payment
under the Collaboration and License Agreement with Genentech. Revenue from customers also included
product sales, royalties, other licence revenue and research revenue. Revenue increased by 145%
compared with the prior year, primarily due to the Genentech upfront payment.
Explanation of Loss
The loss for the year was $7,465,000 (2025: $9,990,000), a decrease of 25% compared with the prior year.
The improvement reflected increased revenue, partly offset by increased investment in research
programs. Research and product development expenditure increased to $11,149,000 (2025: $8,355,000),
net of the Australian Government’s R&D tax incentive, and included the costs associated with advancing
the internal DEP® HER2-Lutetium radiopharmaceutical program and next-generation DEP® candidates.
Net Tangible Assets
Net tangible assets per ordinary share as at 30 June 2026 were $0.03 (30 June 2025: $0.05).
Other
Additional Appendix 4E disclosure requirements, including further commentary on results are contained in
the Annual Report for the year ended 30 June 2026. This report is based on the consolidated financial
statements which have been audited by PricewaterhouseCoopers.
Share your feedback
Discover